Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which test best predicts chemo risks in seniors? new study aims to find out

NCT ID NCT07163169

Knowledge-focused Sponsor: Çanakkale Onsekiz Mart University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at three simple tests—CARG, G8, and a frailty scale—to see which one best predicts chemotherapy side effects in cancer patients aged 65 and older. Researchers will assess 150 patients before they start chemo and track side effects during treatment. The goal is to find the most accurate tool to help doctors make safer treatment decisions for older adults.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose the best screening tool to predict chemotherapy side effects in older adults, leading to safer and more personalized cancer treatment.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve outcomes. The results may not apply to all cancer types or chemotherapy regimens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult oncology patients aged 65 years and older who are scheduled to receive systemic chemotherapy for solid tumors at the Çanakkale Onsekiz Mart University Medical Faculty, Department of Medical Oncology. Eligible participants must have a confirmed cancer diagnosis and a predefined chemotherapy regimen (adjuvant, neoadjuvant, or palliative), but must not have yet started treatment at the time of enrollment.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 65 years or older. * Histologically confirmed cancer diagnosis with a pre-planned chemotherapy regimen (adjuvant, neoadjuvant, or palliative intent). * Chemotherapy not yet initiated at the time of enrollment. * Clinically stable condition, as assessed by the oncologist. * Willingness and ability to provide written informed consent. Exclusion Criteria: * Presence of acute infection or advanced organ failure (cardiac, hepatic, or renal). * Severe psychiatric illness or cognitive impairment that interferes with the ability to complete assessments. * Patients receiving concurrent hormonal therapy, targeted therapy, immunotherapy, or radiotherapy. * Diagnosis of hematologic malignancies (e.g., leukemia, lymphoma, myeloma).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Geriatric oncology Oncology Physiology

Contacts and locations

Locations

  • Çanakkale Onsekiz Mart Univercity

    Çanakkale, 17020, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.